Free Trial

GENPREX (GNPX) Competitors

GENPREX logo
$0.28 -0.01 (-2.33%)
Closing price 04:00 PM Eastern
Extended Trading
$0.28 +0.00 (+1.12%)
As of 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GNPX vs. INKT, PASG, SCYX, DYAI, ENLV, COEP, TPST, NRSN, CVKD, and CGTX

Should you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include MiNK Therapeutics (INKT), Passage Bio (PASG), SCYNEXIS (SCYX), Dyadic International (DYAI), Enlivex Therapeutics (ENLV), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.

GENPREX vs. Its Competitors

MiNK Therapeutics (NASDAQ:INKT) and GENPREX (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$9.51M-$2.52-8.06
GENPREXN/AN/A-$21.11MN/AN/A

MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 84.64%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe MiNK Therapeutics is more favorable than GENPREX.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
GENPREX
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of GENPREX shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 8.5% of GENPREX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics' return on equity of 0.00% beat GENPREX's return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -140.72%
GENPREX N/A -664.65%-370.18%

In the previous week, MiNK Therapeutics had 16 more articles in the media than GENPREX. MarketBeat recorded 16 mentions for MiNK Therapeutics and 0 mentions for GENPREX. GENPREX's average media sentiment score of 1.87 beat MiNK Therapeutics' score of 0.12 indicating that GENPREX is being referred to more favorably in the news media.

Company Overall Sentiment
MiNK Therapeutics Neutral
GENPREX Very Positive

MiNK Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, GENPREX has a beta of -0.5, suggesting that its share price is 150% less volatile than the S&P 500.

Summary

MiNK Therapeutics beats GENPREX on 9 of the 11 factors compared between the two stocks.

Get GENPREX News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNPX vs. The Competition

MetricGENPREXMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.40M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E RatioN/A8.2821.0120.09
Price / SalesN/A303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book1.857.678.125.65
Net Income-$21.11M-$55.28M$3.25B$257.91M
7 Day PerformanceN/A2.50%0.97%2.09%
1 Month Performance-8.31%11.70%7.36%11.13%
1 Year Performance-86.16%4.89%31.31%18.40%

GENPREX Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNPX
GENPREX
1.3581 of 5 stars
$0.28
-2.3%
N/A-85.8%$9.40MN/A0.0020
INKT
MiNK Therapeutics
2.5494 of 5 stars
$7.28
+0.6%
$37.50
+415.5%
+121.4%$28.82MN/A-2.8930Analyst Downgrade
PASG
Passage Bio
2.5741 of 5 stars
$0.43
-6.1%
$7.50
+1,632.1%
-69.3%$28.66MN/A-0.42130Stock Split
SCYX
SCYNEXIS
0.9185 of 5 stars
$0.71
-3.2%
N/A-65.9%$28.54M$3.75M-1.2660Positive News
DYAI
Dyadic International
3.0328 of 5 stars
$0.92
-2.6%
$6.00
+555.4%
-31.5%$28.28M$3.49M-4.587Positive News
Gap Down
ENLV
Enlivex Therapeutics
2.7186 of 5 stars
$1.21
+2.5%
$10.00
+726.4%
-13.7%$27.91MN/A-1.8370Positive News
COEP
Coeptis Therapeutics
0.412 of 5 stars
$7.73
+2.5%
N/A+93.1%$26.49MN/A-1.332
TPST
Tempest Therapeutics
2.3833 of 5 stars
$7.08
-0.7%
$30.00
+323.7%
-75.6%$26.26MN/A-0.3920Positive News
NRSN
NeuroSense Therapeutics
2.5015 of 5 stars
$2.09
+9.4%
$14.00
+569.9%
+150.1%$26.10MN/A-3.8710
CVKD
Cadrenal Therapeutics
2.9665 of 5 stars
$12.95
-0.2%
$32.00
+147.1%
N/A$25.53MN/A-1.404
CGTX
Cognition Therapeutics
2.9505 of 5 stars
$0.58
+42.9%
$2.83
+389.5%
-64.6%$25.11MN/A-0.7820High Trading Volume

Related Companies and Tools


This page (NASDAQ:GNPX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners